P I Industries Ltd (PIIND) Q1 FY27 Earnings Call: Guides Low Single-Digit Growth, Biologicals Surge 50%

P I Industries Ltd held its Q1 FY27 earnings call on August 11, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline Financial Performance

• Revenue of Rs.17,023 million in Q1 FY 2026-2027, with gross margin at 57% and EBITDA margin at 22% (EBITDA Rs.3,693 million).
• Domestic agri-business posted 12% volume growth in Q1 FY 2026-2027, though revenue growth was just 3%; biologicals surged 50% with a three-year CAGR of 15%.
• Export volumes declined 8% and export value fell 12% in Q1 FY 2026-2027; a ~13% rupee depreciation benefit was not fully reflected due to a pass-through model and currency risk management.
• Net working capital improved by 19 days, releasing ~Rs.300 crore; balance sheet remains debt-free with net cash of Rs.38 billion.
• Effective tax rate for FY 2026-2027 expected at ~24%, management noted.

Backlog, Deal Pipeline & Demand Signals

• Order book stood at $1.2 billion as of Q1 FY 2026-2027, stable sequentially; contract assets were Rs.750 crore.
• Pipeline of 90 molecules under development, with 60% at an advanced stage — primarily AgChem, with electronics, pharma, and biologicals.
• Management reiterated FY 2026-2027 revenue growth guidance of lower single digits, subject to industry cycle and conditions, expecting H2 export recovery, new product launches, and gradual scale-up of pharma and global biologicals.
• Management cited early signs of demand stabilisation in the global crop protection market, reinforcing the need for resilient supply chains and diversification.
• Export operating environment remains challenging due to soft commodity prices, muted recovery, and rising geopolitical/vendorisation costs — management remains confident in the medium-to-long-term trajectory.

Molecule Launches, R&D Pipeline & Biologicals

• R&D spending has risen from ~Rs.100 crore to ~Rs.400 crore over the past 3–4 years; management intends to maintain R&D at ~4% of revenue and views it as value creation.
• Management expects to launch four to five molecules in FY 2026-2027 across AgChem, plus a couple in electronics and one or two in pharma.
• PI's biological nematicide is registered in Brazil, Mexico, and the US, with the US launch commencing in FY 2026-2027; India and other markets also planned for launch in the same fiscal. Management cautioned "the product's unique foliar application requires a farmer habit change, which could take time and investment to realise adoption."
• New product (Dichloromezotias) for Diamondback Moth to be launched in FY 2026-2027; anticipated to become a 3-digit revenue product (in Rs. crore) over 5–7 years.
• PI's first NCE insecticide, discovered in India, is set to launch domestically soon, pending regulatory approvals.
• Liprol launch in India expected within FY 2026-2027, subject to regulatory approval; for other geographies, one registration is expected in FY 2027-2028 and another in FY 2028-2029.
• New products contributed 16–18% to CSM segment revenue in Q1 FY 2026-2027.

Profitability Bridge, Subsidiary Losses & Investment Cycle

• Q1 FY 2026-2027 subsidiary EBIT loss was ~Rs.120 crore, with pharma EBIT loss at ~Rs.63 crore; the delta reflects investments in new initiatives like the global biological business.
• Total subsidiary EBITDA loss in Q1 FY 2026-2027 was ~Rs.100 crore (largely from the biological business); the comparable full-year loss for FY 2025-2026 was ~Rs.300 crore overall, with ~Rs.120 crore specifically in global biological.
• EBITDA margin outlook is uncertain due to geopolitical and commodity price volatility; management aims to sustain gross margins through optimisation and agility.
• Pricing pressure across AgChem, CSM, and domestic agrochemicals persists in Q1 FY 2026-2027, driven by challenged demand and low commodity prices; management expects better clarity starting Q2.
• Pharma CRDO order book experienced delays in the quarter, shifting some delivery schedules; management expects revenues to be "securitised" as customers are locked in, and maintained pharma business guidance with potential inter-quarter shifts.
• No timeline was provided for break-even at these subsidiaries; management described the outflows as investments to scale revenue and prove product performance.

Vertical-wise Breakdown & Strategic Initiatives

• Domestic business posted 12% volume growth in Q1 FY 2026-2027, attributed to a delayed sowing season; management is pushing market share rather than raising prices.
• Biologicals portfolio expanded globally with a unique peptide platform, demonstrating consistent performance in the US, Mexico, Brazil, and Asia; a new foliar application nematode product is at par or better than chemical alternatives.
• Global biologicals market is ~$10 billion and growing at a double-digit rate — the only growing segment in crop inputs, management noted.
• PI commissioned one of the world's largest flow chemistry plants to enhance sustainable, safe, and efficient manufacturing capabilities.
• In electronic chemicals, PI has commissioned a commercial plant and begun commercial supplies (implied FY 2026-2027) and is investing in a high-tech manufacturing asset to pursue a differentiated, non-commoditised strategy.
• Pharma CDMO business is showing early positive signs, with a couple of interesting inquiries moving into the commercial phase; QC lab in Italy approved by regulators.

Guidance, Capex & Long-term Outlook

• Q1 FY 2026-2027 capex was Rs.250–260 crore; full-year FY 2026-2027 guidance maintained at Rs.700–800 crore across existing manufacturing, new verticals, and innovation.
• Management expects FY 2026-2027 to be better than FY 2025-2026, driven by H2 export recovery, new product launches, and gradual scale-up of pharma and global biologicals.
• Brazil nematicide market is $750 million; management expects double-digit market share to be achievable over 5–10 years. Last season (FY 2025-2026), farmers tested the product on ~5 million hectares of crops.
• Company signed an exclusive integrated drug discovery partnership with a biotech; evaluating 2–3 similar opportunities to build CRDMO pipeline.
• Management stated PI is moving to the "next dimension/next orbit" with sustainable solutions and biologicals as the top strategic priority for FY 2026-2027 and beyond.
• Investment-level losses at subsidiaries will continue for the "next few quarters" (FY 2026-2027 and beyond) as management front-loads spending to build capabilities and drive future growth.